Adenoid cystic carcinoma of the salivary glands: a pilot study of potential therapeutic targets and characterization of the immunological tumor environment and angiogenesis

Adenoid cystic carcinoma (ACC) is a rare type of cancer commonly occurring in salivary glands. It is characterized by slow but infiltrative growth, nerve infiltration and overall poor prognosis, with late recurrence and distant metastasis. The treatment of ACC is still limited to surgery and/or (adj...

Full description

Saved in:
Bibliographic Details
Main Authors: Michaelides, Ioannis (Author) , Künzel, Julian (Author) , Ettl, Tobias (Author) , Beckhove, Philipp (Author) , Bohr, Christopher (Author) , Brochhausen, Christoph (Author) , Mamilos, Andreas (Author)
Format: Article (Journal)
Language:English
Published: June 2023
In: European archives of oto-rhino-laryngology and head & neck
Year: 2023, Volume: 280, Issue: 6, Pages: 2937-2944
ISSN:1434-4726
DOI:10.1007/s00405-023-07884-3
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00405-023-07884-3
Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s00405-023-07884-3
Get full text
Author Notes:Ioannis Michaelides, Julian Künzel, Tobias Ettl, Philipp Beckhove, Christopher Bohr, Christoph Brochhausen, Andreas Mamilos
Description
Summary:Adenoid cystic carcinoma (ACC) is a rare type of cancer commonly occurring in salivary glands. It is characterized by slow but infiltrative growth, nerve infiltration and overall poor prognosis, with late recurrence and distant metastasis. The treatment of ACC is still limited to surgery and/or (adjuvant) radiotherapy. Till now no promising systemic therapy option exists. However, various studies deliver promising results after treatment with anti-angiogenetic agents, such as anti-EGFR-antibody Cetuximab or Tyrosinkinase inhibitor Lenvatinib.
Item Description:Online veröffentlicht: 1. März 2023
Gesehen am 21.08.2024
Physical Description:Online Resource
ISSN:1434-4726
DOI:10.1007/s00405-023-07884-3